Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. Hormone. British Columbia Cancer Agency, Vancouver, British Columbia, Canada

Survival: 23.8 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: Canada
City/State/Province: Vancouver, British Columbia
Hospital: British Columbia Cancer Agency
Journal: Link
Date: 8/2010

In this study, male patients with metastatic castration-resistance prostate cancer were separated into two treatment groups, called arm A and arm B. Both arms consisted of 41 patients and the median age of each group was 69 years.

Patients in arm A were given a combination of the chemotherapy agent docetaxel with prednisone (to act as an anti-inflammatory medication) and a drug called OGX-011. OGX-011 is a biologic therapy that targets and blocks a protein called clusterin, which promotes cancer cell growth.

Patients in arm B were given docetaxel and prednisone only.

The highest toxicity level reported for either arm was grade 4 and included leucopenia and neutropenia. In addition, most patients (100% of arm A, 95% of arm B) reported fatigue of grade 1-4. Other toxicities included diarrhea, nausea, and myalgia (muscle pain).

The median overall survival was 23.8 months in arm A and 16.9 months in arm B. Median progression-free survival in arm A and arm B was 7.3 and 6.1 months, respectively.

Some of the authors are associated with OncoGenex Technologies (makers of OGX-011) and/or Sanofi-Aventis (maker of docetaxel).

Correspondence: Dr. Kim N. Chi; email:

E-mail to a Friend Email Physician More Information